Phare Bio Analysis: $27M Raised
What is Phare Bio?
Phare Bio is a social venture utilizing generative AI and deep learning to discover new classes of antibiotics. The company collaborates with the Collins Lab at MIT and is supported by organizations like TED's Audacious Project and Google.org. Phare Bio aims to address the antimicrobial resistance crisis by developing novel antibiotics through its AIBiotics platform.
Location
303 Congress Street, Boston, Massachusetts, United States
Employees
11-50
Founded
2020
Funding Status
Seed
Product Features & Capabilities
- AIBiotics generative AI antibiotics discovery engine
- Hit-to-Lead Optimization
- Preclinical Development
- Clinical Development
Use Cases
Design novel antibiotics against Acinetobacter baumannii; Develop antibiotics for Pseudomonas aeruginosa; Conduct drug metabolism and toxicology assays; Test drug delivery in preclinical studies; Partner with pharma for clinical trials
Other Considerations
Selected for Google.org's Generative AI Accelerator; Backed by TED's Audacious Project; Received $27 million from ARPA-H; Named to Fast Company’s 2025 World Changing Ideas list; Winner of Newsweek’s AI Impact Award
See something that needs updating? Suggest edits to this profile.